<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940093</url>
  </required_header>
  <id_info>
    <org_study_id>ImMiGeNe-001</org_study_id>
    <nct_id>NCT02940093</nct_id>
  </id_info>
  <brief_title>Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers</brief_title>
  <acronym>ImMiGeNe</acronym>
  <official_title>Implementation of a Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers for Stratified Clinical Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combined analysis of microbiome, immunological parameters and host genetics in patients
      has potential for applying personalized approaches of prevention, diagnostics or therapy in
      the future. However, the acquisition and analysis of these patient characteristics in a
      scientifically sound, technically reliable, cost-effective, practicable and future-oriented
      fashion are a far from trivial task. Therefore the objectives of the study are (i) to
      optimize a sample and data acquisition and analysis pipeline that fulfills these criteria
      (using samples from healthy volunteers); (ii) validate the pipeline in a cohort of children
      undergoing stem cell transplantation, yielding information on host immuno-genetics, gut
      immune function and the human gut microbiome; (iii) deduct the most critical parameters for
      host-microbiome interplay from this complex dataset.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune system - intestinal microbiota co-re-emergence after myeloablative conditioning and antibiotics treatment, respectively.</measure>
    <time_frame>through study completion, anticipated after 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Stem cell transplant recipient</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cell donor</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stem cell transplantation</intervention_name>
    <description>Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.</description>
    <arm_group_label>Stem cell transplant recipient</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Feces Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing stem cell transplantation due to hematological malignancies Allogeneic
        stem cell donors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (stem cell recipient) with hematological malignancies, age 3-18

          -  Healthy allogeneic stem cell donor (identical or non-identical related donor)

        Exclusion Criteria:

          -  Patients &lt;3 years of age

          -  Patient who are unable to provide urine, stool or blood samples due to their medical
             condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander NR Weber, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander NR Weber, PhD</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>87623</phone_ext>
    <email>alexander.weber@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silke Peter, MD</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>81527</phone_ext>
    <email>silke.peter@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lang, MD</last_name>
      <phone>07071</phone>
      <phone_ext>83781</phone_ext>
      <email>Peter.Lang@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

